Acurion provides oncologists with actionable genomic data at the biopsy stage through its OncoGaze™ platform, enabling more cancer patients to be matched with FDA‑approved precision therapies. By integrating insights from leading oncologists and top‑cited cancer researchers, the technology streamlines the decision‑making workflow and expands access to targeted treatments across multiple cancer types. OncoGaze aims to increase the proportion of patients receiving optimal, genomics‑guided care.

Alume Biosciences is developing bevonescein, a nerve illumination compound that enhances the visibility of critical nerves during surgery through fluorescence. This technology aims to reduce the incidence of nerve damage, which can lead to severe complications such as incontinence and facial paralysis in patients undergoing surgical procedures.

Amply is a cloud-based email delivery service that transforms transactional email data into actionable insights, enabling companies to enhance product development and user engagement. By utilizing intelligent routing and real-time monitoring, Amply addresses issues of email deliverability and infrastructure health, ensuring optimal placement in users' inboxes.

BioAtla develops Conditionally Active Biologics (CABs) that are engineered to activate selectively in the tumor microenvironment, enhancing tumor selectivity and reducing on-target toxicity. This technology aims to improve the therapeutic index of cancer treatments, providing safer and more effective immunotherapies.

Dreamscape Immersive utilizes virtual reality technology to create immersive, location-based entertainment experiences that engage users in interactive storytelling. This approach addresses the demand for novel entertainment options in a market saturated with traditional media.

DWE provides rugged, USB‑C compliant vision cameras built for subsea environments, featuring aerospace‑grade aluminum housings, sapphire viewports, and quartz lenses that withstand pressures up to 11,000 m. The cameras consume ≤1.5 W, deliver HD video with built‑in H.264 compression, and support plug‑and‑play integration via USB 2.0, enabling up to seven synchronized streams for ROV, AUV, and ASV applications. Their open‑source DWE OS software offers configurable IP‑camera control and AI‑enhanced image processing for reliable navigation, inspection, and 3D mapping.

This company offers mobile diagnostic labs that can be rapidly deployed to any healthcare setting. Their system performs a wide range of tests on-site, delivering results in under 30 minutes, while more complex tests are handled by a central lab, improving patient care and reducing healthcare resource utilization.

MatriSys Bio is developing a novel class of biopharmaceuticals that utilize beneficial bacteria derived from healthy human skin to treat chronic inflammatory skin conditions. This approach aims to restore skin homeostasis for millions of patients suffering from dermatological diseases such as atopic dermatitis and acne, reducing reliance on steroids and antibiotics.

NeuraLace offers Axon Therapy®, a 100% non-invasive magnetic Peripheral Nerve Stimulation (mPNS) device designed to treat chronic neuropathic pain without the need for needles or surgical interventions. This technology provides significant pain reduction, minimizing reliance on opioids and improving patient quality of life through targeted neuromodulation.

Oncternal Therapeutics is a clinical-stage oncology company developing targeted therapies for hematological malignancies and prostate cancer by exploring untapped biological pathways involved in cancer progression. The company addresses the critical unmet medical needs of patients with these cancers through its diverse pipeline of treatment modalities.

ProciseDx provides point-of-care therapeutic drug monitoring (TDM) solutions for infliximab and adalimumab, delivering lab-quality results in under five minutes. This technology enables gastroenterologists to obtain critical drug concentration information promptly, enhancing patient management for those with inflammatory bowel diseases.

Tempo Therapeutics utilizes proprietary Microporous Annealed Particle (MAP) technology to create fully synthetic, injectable scaffolds that modulate immune responses for tissue regeneration. This approach addresses the challenge of inflammatory and scar-forming reactions in soft tissue reconstructions, promoting the formation of vascularized tissue and improving patient outcomes.

VelosBio develops novel antibody-drug conjugates specifically targeting hematological cancers, utilizing a precise mechanism to deliver cytotoxic agents directly to cancer cells. This approach aims to improve treatment efficacy while minimizing systemic toxicity associated with traditional chemotherapy.